FINWIRES · TerminalLIVE
FINWIRES

研究快讯:力拓铜当量产量增长9%;2026年业绩指引维持不变

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下:力拓2026年第一季度业绩稳健,尽管面临天气挑战,铜当量产量仍增长9%。铁矿石产量达到7880万吨(增长13%),表现强劲,但由于热带气旋导致约800万吨的运输中断,销量增长受限,仅为7240万吨,增幅为2%。我们认为,力拓多元化的产品组合展现了其韧性和规模优势,其中奥尤陶勒盖铜矿产量飙升56%至10.2万吨,西芒杜铜矿也实现了首次全面出货里程碑。尽管受到天气影响,管理层仍维持2026年业绩指引,这体现了对运营执行的信心。公司已成功实施全部6.5亿美元的生产力提升计划,并完成了Resolution Copper土地交换,目前正在全球最大的未开发铜矿之一进行钻探。我们预计铝业务将继续保持强劲增长势头,奥尤陶勒盖铝业公司将在 2028 年至 2036 年间逐步实现年产 50 万吨的目标,尽管两起工作场所死亡事故凸显了管理层对安全问题的重新重视。

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA